Skip to main content
    C

    Cadrenal Therapeutics, Inc. Common Stock (CVKD)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.40
    -0.11 (-7.28%)

    Market Cap: $5.39M

    Last updated: Nov 17, 2026 at 11:02 AM ET

    Cadrenal Therapeutics, Inc. Common Stock (CVKD) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect Cadrenal Therapeutics, Inc. Common Stock (CVKD) to earn -$3.92 per share in the fiscal year ending Dec 31, 2026. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 0 down. For the fiscal year ending Dec 31, 2027, the EPS consensus is -$3.41.

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus shows a smaller loss.

    Fiscal year ending Dec 31, 2026
    -$3.92
    EPS consensus
    Fiscal year ending Dec 31, 2027
    -$3.41
    EPS consensus
    Next report
    Mar 29, 2027
    Estimated

    EPS range

    Fiscal year endingEPS consensusEPS rangeEPS analysts
    Dec 31, 2026-$3.92-$3.92 to -$3.912
    Dec 31, 2027-$3.41-$3.55 to -$3.262

    Quarterly Estimates

    Quarter endingEPS consensusEPS rangeEPS analysts
    Dec 31, 2026-$0.88N/A5

    Estimate Revisions

    Across the 2 periods below, the last 30 days brought 2 upward and 0 downward EPS revisions. Raises outnumber cuts in every period.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 202610
    Fiscal year ending Dec 31, 202710

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$5.88.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026-$3.92-$3.92-$3.19-$7.74-$5.88N/A
    Fiscal year ending Dec 31, 2027-$3.41-$3.41-$3.09-$3.91-$3.91N/A

    Frequently Asked Questions About CVKD

    What is the CVKD stock forecast?

    Consensus analyst estimates put Cadrenal Therapeutics, Inc. Common Stock's EPS at -$3.92 for the fiscal year ending Dec 31, 2026.

    What EPS do analysts expect from CVKD next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$3.92, with estimates from -$3.92 to -$3.91 from 2 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$3.41, with estimates from -$3.55 to -$3.26 from 2 analysts.

    How many analysts cover CVKD?

    2 analysts estimate EPS for Cadrenal Therapeutics, Inc. Common Stock for the fiscal year ending Dec 31, 2026.